Genzyme Europe B.V.

genzyme.com

Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before.Genzyme has pioneered the development and delivery of transformative therapies for over 30 years.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

SPECIFIC BIOLOGICS INC. ANNOUNCES THERAPEUTIC DEVELOPMENT AWARD FROM THE CYSTIC FIBROSIS FOUNDATION

Specific Biologics Inc. | December 08, 2021

news image

Specific Biologics Inc. an early-stage biotechnology company developing novel gene editing technologies, announced that it will receive more than US$527,000 to support the preclinical development of its Dualase™ gene editing platform to target a set of cystic fibrosis -causing nonsense mutations where patients currently have fewer therapeutic options available. "Incredible advancements in the treatment of cystic fibrosis have been made since the id...

Read More

OXITEC UNVEILS FIRST FIELD TRIAL RESULTS FOR CROP-PROTECTING GM MOTHS

Labiotech.eu | January 28, 2020

news image

A study led by Oxitec has shown for the first time that diamondback moths genetically engineered to produce only male offspring can survive in the wild, a solution that shows promise for cutting populations of the crop pest. Caterpillars of the diamondback moth Plutella xylostella are one of the most destructive pests for growers of cabbages, broccoli and cauliflowers. Rising resistance to insecticides is making it progressively more difficult for farmers to deal with the insects effectively....

Read More

MedTech, Industrial Impact

PUMA BIOTECHNOLOGY PRESENTS UPDATED FINDINGS FROM THE TBCRC-022 TRIAL AT THE 2022 SAN ANTONIO BREAST CANCER SYMPOSIUM

Puma Biotechnology | December 08, 2022

news image

Puma Biotechnology, Inc. a biopharmaceutical company, presented updated findings from the Translational Breast Cancer Research Consortium Trial 022 at the ongoing 2022 San Antonio Breast Cancer Symposium in San Antonio, Texas. The poster entitled “Neratinib and ado-Trastuzumab-Emtansine for HER2+ Breast Cancer Brain Metastases Translational Breast Cancer Research Consortium Trial 022,” was presented by Rachel A Freedman, MD, MPH, Breast Oncology Center, Susan F. Smith Center for Wome...

Read More

Research

MEDOLIFE RX ANNOUNCES CHANGES TO MANAGEMENT AND IMPROVEMENTS TO AELIA’S MARKETING EFFORTS

Medolife Rx, Inc. | February 07, 2022

news image

Medolife Rx, Inc. a global integrated biopharmaceutical company with manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. that the Company is in progress of revamping their online marketing platform, starting off with a change in the marketing and brand development for their AELIA brand wellness products that utilize the company’s polarized ingredients. Medolife believes these changes will bring greater product awareness and improved online...

Read More
news image

Cell and Gene Therapy

SPECIFIC BIOLOGICS INC. ANNOUNCES THERAPEUTIC DEVELOPMENT AWARD FROM THE CYSTIC FIBROSIS FOUNDATION

Specific Biologics Inc. | December 08, 2021

Specific Biologics Inc. an early-stage biotechnology company developing novel gene editing technologies, announced that it will receive more than US$527,000 to support the preclinical development of its Dualase™ gene editing platform to target a set of cystic fibrosis -causing nonsense mutations where patients currently have fewer therapeutic options available. "Incredible advancements in the treatment of cystic fibrosis have been made since the id...

Read More
news image

OXITEC UNVEILS FIRST FIELD TRIAL RESULTS FOR CROP-PROTECTING GM MOTHS

Labiotech.eu | January 28, 2020

A study led by Oxitec has shown for the first time that diamondback moths genetically engineered to produce only male offspring can survive in the wild, a solution that shows promise for cutting populations of the crop pest. Caterpillars of the diamondback moth Plutella xylostella are one of the most destructive pests for growers of cabbages, broccoli and cauliflowers. Rising resistance to insecticides is making it progressively more difficult for farmers to deal with the insects effectively....

Read More
news image

MedTech, Industrial Impact

PUMA BIOTECHNOLOGY PRESENTS UPDATED FINDINGS FROM THE TBCRC-022 TRIAL AT THE 2022 SAN ANTONIO BREAST CANCER SYMPOSIUM

Puma Biotechnology | December 08, 2022

Puma Biotechnology, Inc. a biopharmaceutical company, presented updated findings from the Translational Breast Cancer Research Consortium Trial 022 at the ongoing 2022 San Antonio Breast Cancer Symposium in San Antonio, Texas. The poster entitled “Neratinib and ado-Trastuzumab-Emtansine for HER2+ Breast Cancer Brain Metastases Translational Breast Cancer Research Consortium Trial 022,” was presented by Rachel A Freedman, MD, MPH, Breast Oncology Center, Susan F. Smith Center for Wome...

Read More
news image

Research

MEDOLIFE RX ANNOUNCES CHANGES TO MANAGEMENT AND IMPROVEMENTS TO AELIA’S MARKETING EFFORTS

Medolife Rx, Inc. | February 07, 2022

Medolife Rx, Inc. a global integrated biopharmaceutical company with manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. that the Company is in progress of revamping their online marketing platform, starting off with a change in the marketing and brand development for their AELIA brand wellness products that utilize the company’s polarized ingredients. Medolife believes these changes will bring greater product awareness and improved online...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us